Journal of Blood & Lymph

Department of Inflammation and Immunity, Cleveland Clinic, Cleveland OH, USA

Publications

• Mini Review   
  CD6 as a Therapeutic Target for Autoimmune Disease and Cancer
  Author(s): Xiaoxian Zhao, Feng Lin and Eric D. Hsi*
  
  CD6 is one of the first discovered lymphocyte receptors. It is expressed on all T cells, a NK cell subset, and B-lymphocyte B1a subsets. CD6 is involved in cell-to-cell interaction and modulation of adaptive immune responses. It is also implicated in the pathogenesis of a variety of immune-mediated conditions. CD6 and its two major known ligands (CD166 and CD318) have emerged as new therapeutic targets for autoimmune diseases. Recent studies explored the distribution of CD6 in both T-cell lymphomas and aggressive NK/T cell neoplasms, and evaluated the activities of CD6-antibody drug conjugate in both in vitro and in vivo mouse models for these malignancies. In this mini-review, we highlight the current understanding of CD6 as a therapeutic target in autoimmune disease, T cell lymphoma and aggressive NK/T cell neoplasms... Read More»
  DOI: 10.37421/2165-7831.2024.14.333

  Abstract HTML PDF